S. Paolini

发表

Imatinib mesylate in the treatment of hematologic malignancies

M. Baccarani, P. Piccaluga, M. Rondoni, 2007, Expert opinion on biological therapy.

Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature

S. Pileri, M. Baccarani, S. Ascani, 2007, Histopathology.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

M. Baccarani, P. Piccaluga, M. Rondoni, 2007, Haematologica.

Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature

Russell E. Lewis, S. Paolini, F. Bonifazi, 2019, Mycoses.

Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

M. Baccarani, S. Paolini, G. Rosti, 2006, Clinical Cancer Research.

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol

R. Foà, S. Chiaretti, A. Vitale, 2019, Leukemia & lymphoma.

Ubiquitin-proteasome system is a sensitive target in Ph + leukemia

P. Piccaluga, M. Rondoni, S. Paolini, 2009 .

Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights

S. Paolini, C. Finelli, S. Parisi, 2022, Expert review of hematology.

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

S. Rutella, J. Dipersio, P. Chevallier, 2020, Blood.

acute myeloid leukemia patients ligand-mismatched natural killer cells after infusion in elderly high risk Successful transfer of alloreactive haploidentical KIR

M. Baccarani, L. Ruggeri, A. Velardi, 2011 .

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

M. Baccarani, L. Ruggeri, A. Velardi, 2011, Blood.

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

P. Bartolomeo, R. Foà, P. Galieni, 2017 .

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

S. Pileri, E. Sabattini, P. Piccaluga, 2011, Leukemia & lymphoma.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

M. Baccarani, P. Piccaluga, M. Rondoni, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conditioning regimens in acute myeloid leukemia

P. Piccaluga, S. Paolini, G. Visani, 2014, Expert review of hematology.

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

S. Paolini, G. Martinelli, A. Martelli, 2011, Leukemia.

Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients

S. Paolini, G. Martinelli, A. Martelli, 2012, Leukemia.

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

T. Haferlach, M. Steurer, S. Paolini, 2017, Leukemia.

Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukaemia

P. Piccaluga, S. Paolini, F. Bonifazi, 2012 .

Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation.

M. Triggiani, M. Baccarani, P. Piccaluga, 2007 .

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

M. Baccarani, S. Paolini, G. Rosti, 2009, Blood.

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients

S. Paolini, A. Curti, M. Cavo, 2020, Microorganisms.

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol

M. Vignetti, M. Voso, S. Paolini, 2022, Cancers.

Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.

S. Paolini, G. Martinelli, M. Luppi, 2014, Leukemia research.

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

M. Baccarani, S. Paolini, G. Martinelli, 2014, Cancer.

Achieving aMajor Molecular Response at theTime of a Complete Cytogenetic Response ( CCgR ) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

M. Baccarani, S. Paolini, G. Rosti, 2006 .

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

S. Paolini, G. Martinelli, I. Iacobucci, 2008, Clinical advances in hematology & oncology : H&O.

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.

R. Hills, N. Russell, M. Dennis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

R. Foà, P. Galieni, M. Baccarani, 2021, Blood advances.

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

R. Foà, S. Chiaretti, A. Vitale, 2018, Haematologica.

Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up

F. Gherlinzoni, S. Paolini, G. Martinelli, 2015, American journal of hematology.

FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.

Valeria Nofrini, C. Mecucci, S. Paolini, 2012, Leukemia research.

Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents

S. Paolini, E. Ottaviani, C. Papayannidis, 2022, European journal of haematology.

New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

P. Piccaluga, S. Paolini, G. Martinelli, 2009 .

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

S. Paolini, G. Martinelli, C. Papayannidis, 2017, BMC Cancer.

Darbepoetin Alpha For the Treatment of Anemia in Systemic Mastocytosis

P. Piccaluga, M. Rondoni, S. Paolini, 2019, Biomedical Journal of Scientific & Technical Research.

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab‐ozogamicin in adult refractory B‐acute lymphoblastic leukemia

M. Baccarani, S. Paolini, G. Martinelli, 2009, American journal of hematology.

Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters

L. Ruggeri, A. Velardi, S. Paolini, 2022, Frontiers in Immunology.

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl‐positive acute lymphoid leukaemia

M. Baccarani, P. Piccaluga, M. Rondoni, 2004, European journal of haematology.

Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia

S. Pileri, B. Falini, E. Sabattini, 2009, Leukemia.

Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment

S. Paolini, G. Martinelli, C. Papayannidis, 2022, Hematological oncology.

Randomized clinical trials comparing autologous stem cell transplantation and chemotherapy or no further therapy

S. Paolini, G. Meloni, F. Ferrara, 2018 .

Autologous Stem Cell Transplantation for Acute Myeloid Leukemia

P. Piccaluga, S. Paolini, G. Meloni, 2013 .

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

M. Gobbi, R. Fanin, P. Mazza, 2008, European journal of haematology.

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia

S. Paolini, G. Martinelli, E. Dajti, 2021, Cancer medicine.

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

M. Baccarani, S. Paolini, G. Martinelli, 2010, Leukemia research.

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

R. Foà, M. Baccarani, S. Chiaretti, 2008, Haematologica.

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.

R. Foà, M. Baccarani, S. Chiaretti, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale for allogeneic SCT : the graft versus leukaemia effect in ALL

P. Piccaluga, S. Paolini, F. Bonifazi, 2022 .

Identiﬁcation and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1 –positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMAAL WP)

R. Foà, M. Baccarani, S. Chiaretti, 2009 .

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

S. Paolini, C. Papayannidis, S. Soverini, 2021, Hematological oncology.

MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia

M. Baccarani, S. Paolini, G. Martinelli, 2020, European journal of haematology.

Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B.

M. Baccarani, S. Paolini, C. Agostinelli, 2006, The Journal of infection.

Daunorubicin for the treatment of acute myeloid leukemia

P. Piccaluga, S. Paolini, G. Visani, 2014 .

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients

S. Paolini, G. Martinelli, E. Ottaviani, 2015, Oncotarget.

Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia

M. Baccarani, S. Paolini, G. Martinelli, 2008, Hematology.

Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients

R. Foà, M. Baccarani, S. Chiaretti, 2010, Leukemia.

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

M. Konopleva, M. Andreeff, S. Paolini, 2022, Blood.

CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients

R. Foà, M. Baccarani, A. Vitale, 2011, Clinical Cancer Research.

CDKN2A/BAlterations Impair Prognosis in AdultBCR-ABL1– Positive Acute Lymphoblastic Leukemia Patients

M. Baccarani, A. Vitale, M. Vignetti, 2011 .

Imaging , Diagnosis , Prognosis CDKN 2 A / B Alterations Impair Prognosis in Adult BCR-ABL 1 – Positive Acute Lymphoblastic Leukemia Patients

M. Baccarani, A. Vitale, M. Vignetti, 2011 .

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery

G. Castellani, L. Bullinger, T. Haferlach, 2018, Cancer.

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation

P. Piccaluga, S. Paolini, G. Rosti, 2012, Journal of blood medicine.

Pathobiology of acute lymphoblastic leukemia.

S. Pileri, E. Sabattini, P. Piccaluga, 2011, Seminars in diagnostic pathology.

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).

R. Foà, M. Baccarani, S. Chiaretti, 2009, Blood.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

R. Larson, S. Paolini, G. Martinelli, 2019, The New England journal of medicine.

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.

R. Foà, M. Baccarani, S. Chiaretti, 2008, Blood.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study

M. Baccarani, M. Rondoni, S. Paolini, 2007, Haematologica.

Hypereosinophilic syndrome and molecularly targeted therapy

M. Baccarani, M. Rondoni, S. Paolini, 2007 .

The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party

R. Foà, M. Baccarani, A. Vitale, 2010, Haematologica.

Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing

P. Piccaluga, S. Paolini, G. Visani, 2023, Hemato.

Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care?

S. Pileri, P. Piccaluga, S. Paolini, 2012, Expert review of hematology.

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemia

P. Piccaluga, S. Paolini, G. Martinelli, 2007, Cancer.

Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).

M. Baccarani, P. Piccaluga, M. Rondoni, 2006 .

Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients.

S. Ascani, P. Piccaluga, S. Paolini, 2018, Polish journal of pathology : official journal of the Polish Society of Pathologists.

Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients

S. Pileri, P. Piccaluga, S. Paolini, 2014, Leukemia.

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

R. Foà, M. Baccarani, A. Vitale, 2011, Haematologica.

SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis

S. Pileri, F. Alesiani, P. Piccaluga, 2011, PloS one.

Long-term molecular complete remission with IFN-α in Ph+ adult acute lymphoid leukemia patients

M. Baccarani, P. Piccaluga, M. Rondoni, 2008, Leukemia.

Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration.

M. Baccarani, S. Paolini, G. Martinelli, 2010, Leukemia research.

A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever

P. Piccaluga, S. Paolini, L. Bolondi, 2019, Case reports in hematology.

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

S. Paolini, G. Martinelli, C. Papayannidis, 2018, BMC Cancer.

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

M. Konopleva, M. Andreeff, S. Paolini, 2019, Blood.

Acute Myeloid Leukemia Mutations: Therapeutic Implications

S. Paolini, C. Papayannidis, A. Curti, 2019, International journal of molecular sciences.

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

J. McCubrey, S. Paolini, A. Pession, 2023, Clinical Epigenetics.

Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.

S. Paolini, G. Martinelli, E. Ottaviani, 2020, Leukemia research.

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.

R. Fanin, M. Baccarani, P. Piccaluga, 2007, Haematologica.

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

R. Fanin, M. Baccarani, P. Piccaluga, 2005, Blood.

S. Rutella, S. Paolini, E. Ottaviani, 2021, Blood advances.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Complete paraplegia after Nelarabine treatment in a T‐cell acute lymphoblastic leukemia adult patient

M. Baccarani, S. Paolini, G. Martinelli, 2010, American journal of hematology.

Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience

M. Cazzola, R. Foà, M. Baccarani, 2015 .

S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

S. Paolini, G. Martinelli, C. Récher, 2019, HemaSphere.

Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.

M. Baccarani, M. Rondoni, S. Paolini, 2007 .

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

Giovanni Martinelli, Ilaria Iacobucci, Cristina Papayannidis, 2016, Oncotarget.

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

P. Piccaluga, S. Paolini, F. Ferrara, 2017, Leukemia research.

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

M. Baccarani, M. Rondoni, S. Paolini, 2007, The Lancet. Oncology.

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

P. Pelicci, E. Sabattini, S. Paolini, 2018, Journal of Hematology & Oncology.

Use of Next Generation Sequencing to Define the Origin of Primary Myelofibrosis

P. Piccaluga, S. Paolini, M. Etebari, 2023, Cancers.

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.

M. Baccarani, M. Rondoni, S. Paolini, 2008 .

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia

A. Grassi, S. Paolini, M. Mancini, 2021, Frontiers in Oncology.

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML

S. Paolini, G. Martinelli, E. Ottaviani, 2016, Expert opinion on pharmacotherapy.

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia

S. Paolini, G. Martinelli, G. Simonetti, 2019, Cancers.

The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study

R. Fanin, S. Paolini, E. Ottaviani, 2023, Cancer Medicine.

Abstract CT184: Gilteritinib significantly prolongs overall survival in patients withFLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial

R. Larson, S. Paolini, G. Martinelli, 2019, Clinical Trials.

Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party

R. Foà, R. Fanin, M. Baccarani, 2008 .

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report

S. Paolini, G. Martinelli, C. Papayannidis, 2017, BMC Cancer.

FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features

S. Paolini, G. Martinelli, C. Papayannidis, 2016, American journal of hematology.

Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408

M. Cazzola, R. Foà, M. Baccarani, 2014 .

Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge

M. Baccarani, P. Zinzani, S. Paolini, 2008, Leukemia & lymphoma.

Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement

S. Paolini, C. Papayannidis, F. Bonifazi, 2021, Acta Haematologica.

Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients.

M. Baccarani, S. Paolini, G. Martinelli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.

M. Baccarani, P. Piccaluga, M. Rondoni, 2006 .

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

M. Baccarani, C. Mecucci, P. Piccaluga, 2005 .

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.

M. Baccarani, P. Piccaluga, M. Rondoni, 2004, Haematologica.

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

M. Cazzola, R. Fanin, M. Baccarani, 2012 .

"This is the peer reviewed version of the following article: “Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up”

F. Gherlinzoni, S. Paolini, A. Piccin, 2015 .

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.

R. Foà, M. Baccarani, S. Chiaretti, 2008, Blood.

M. Baccarani, S. Paolini, G. Rosti, 2009, Blood.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

G. Garcia-Manero, S. Paolini, P. Fenaux, 2023, The Lancet.

Four Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid Leukemia Patients.

R. Fanin, F. Gherlinzoni, M. Baccarani, 2009 .

RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.

D. Amadori, M. Gobbi, R. Fanin, 2009 .

Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

P. Pasini, I. Naldi, S. Paolini, 2023, American journal of hematology.

Complete paraplegia after Nelarabine treatment in a T‐cell acute lymphoblastic leukemia adult patient

M. Baccarani, S. Paolini, G. Martinelli, 2010, American journal of hematology.